If you have been reading about deamidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-20. Numbers and descriptions here follow the published literature rather than marketing material.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
On 18 October, the Brazilian government took a resolution to the UN Security Council that dealt with the Israel-Hamas conflict. In the proposal, plans to provide basic supplies to civilians in conflict situations, such as water and medicine, as well as calls for the release of Israelis held hostage by Hamas, creation a humanitarian corridor and protection of the physical integrity of civilians were some of the topics discussed; the resolution received 12 votes in favour, but was vetoed due to the opposing vote by the United States.
This is a list of investigational substance-related disorder drugs, or drugs that are currently under development for clinical use for the treatment of substance-related disorders but are not yet approved. Substance-related disorders include substance use disorders like alcoholism (alcohol use disorder), amphetamine use disorder, cocaine use disorder, nicotine use disorder, and opioid use disorder, among others. In addition, they include substance withdrawal syndromes like alcohol withdrawal and opioid withdrawal as well as substance overdoses like opioid overdose. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". This list was last comprehensively updated in January 2026. It is likely to become outdated with time.
== Ethnic groups == The Moluccans homeland is divided into two provinces which are part of the Maluku Islands, namely the provinces of Maluku and North Maluku. Each has ethnic diversity, there are many different ethnic groups in Maluku Islands, and they are a mixture of Austronesian and Melanesian.
== Notable people == Neal Asher, science fiction writer, born in Billericay Francis Thomas Bacon, engineer, born in Billericay Lee Barnard, footballer, went to school in Billericay Peter Bone, politician, born in Billericay Louise Boyce, model and writer, born in Billericay Nick Cater, author and journalist in Australia, born in Billericay Daniel Corbett, TV weather forecaster, lived in Billericay as a child Robert Denmark, middle- and long-distance athlete Justin Edinburgh, footballer, lived in Billericay, played for Tottenham Hotspur; played for and managed Billericay Town Lee Evans, comedian, went to school and lives in Billericay Mark Foster, swimmer, born in Billericay David Gandy, model, born and went to school in Billericay Wrey Gardiner, poet, editor and publisher, founded The Grey Walls Press in Billericay Teresa Gorman, politician, the constituency's high-profile former MP Lee Harrison, footballer, born in Billericay Chris Haywood, actor/producer, born in Billericay David Hopwood, banker, born in Billericay Ralph Izzard, journalist, born in Billericay Marshall Jefferson, music producer, lived in Billericay Perry McCarthy, racing driver Suzanne Maddock, actor, lives in Billericay Christopher Martin, Mayflower pilgrim, lived in Billericay Alison Moyet, pop singer, born in Billericay Richard Osman, TV producer and personality ("Pointless Friend" on BBC show Pointless), born in Billericay Kevin Painter, darts player, born in Billericay Paul Parker, was raised in Billericay and lived there when he became a professional footballer.
where M = Cu (n = 1); Mn (n = 2); Fe (n = 2); Ni (n = 2). In this reaction the oxidation state of the metal cation oscillates between n and n + 1. Catalase, which is concentrated in peroxisomes located next to mitochondria, reacts with the hydrogen peroxide to catalyze the formation of water and oxygen. Glutathione peroxidase reduces hydrogen peroxide by transferring the energy of the reactive peroxides to a sulfur-containing tripeptide called glutathione. The sulfur contained in these enzymes acts as the reactive center, carrying reactive electrons from the peroxide to the glutathione. Peroxiredoxins also degrade H2O2, within the mitochondria, cytosol, and nucleus.
Sources: en.wikipedia.org
== Applications == In the synthesis of aspartame, less bitter-tasting byproduct is produced when the reaction is catalyzed by thermolysin. Determining protein stability in cell lysate using the fast parallel proteolysis (FASTpp) assay.
Lastly, the sixth variant (K5R_I10H_F12W) was developed by combining the amino acid substitutions of the first and second variants. Moreover, researchers from the Clemens-Schöpf Institute of Organic Chemistry and Biochemistry and Helmholtz-Institute for Pharmaceutical Research Saarland, developed potent synthetic human matriptase-1 inhibitors based on a different SFTI-1 variant, SDMI-1. SFTI-1 derived matriptase inhibitor-1 (SDMI-1) was previously developed by replacing residue 10 of SFTI-1 (isoleucine, I) with arginine (R) and residue 12 (phenylalanine, F) with histidine (H). Further modifications of SDMI-1 resulted in synthetic matriptase-1 inhibitors with improved inhibitory activity, matriptase binding, and inhibition potency. The SDMI-1 variant that resulted in enhanced inhibitory activity was developed by replacing residue 1 of SDMI-1 (glycine, G) with lysine (K) and by keeping it as a monocyclic structure. The SDMI-1 variant that resulted in improved matriptase binding was created by using the same amino acid substitutions of the previously mentioned SDMI-1 variant and by attaching a bulky fluorescein moiety to the side chain of lysine. Lastly, the SDMI-1 variant that had enhanced inhibition potency was developed by applying the same amino acid substitutions of the previous variants, cleaving the proline-aspartic acid sequence found at the C-terminus (PD-OH), and by making it a bicyclic compound via tail-to-side-chain cyclization.
== The Mkhedrioni after Gamsakhurdia == The Mkhedrioni played a crucial role in suppressing the remaining "Zviadists" after the downfall of Gamsakhurdia. Eduard Shevardnadze, a former Soviet foreign minister, was brought in to provide a respectable face for the new government, but it remained dependent on the Mkhedrioni: even inside the parliament building, Mkhedrioni gunmen had a constant presence as "bodyguards" for Jaba Ioseliani, who was now a member of parliament. Mkhedrioni were given the role of the interior forces under the new government. In 1993, worsening civil strife in Abkhazia prompted the Mkhedrioni and National Guard to launch a joint operation in the region to root out separatists and Gamsakhurdia supporters. This resulted in a disastrous defeat for the pro-government forces, who were driven out of Abkhazia along with virtually the entire ethnic Georgian population of the region: over 10,000 people were killed in the fighting. In September 1993, Gamsakhurdia took the opportunity to launch an armed uprising in western Georgia in an attempt to return to power. The Mkhedrioni played an important role in suppressing the uprising and were for a while given semi-official status as the "Georgian Rescue Corps". Russian intervention ensured Gamsakhurdia's defeat and on December 31 he reportedly committed suicide, though it has also been stated, and widely believed within Georgia, that he was murdered. Mkhedrioni forces were alleged in press reports to be responsible for his death, but they denied this.
Polar is a 2019 neo-noir action thriller film directed by Jonas Åkerlund and written by Jayson Rothwell, based on Víctor Santos's 2013 graphic novel Polar: Came From the Cold. The film stars Mads Mikkelsen, Vanessa Hudgens, Katheryn Winnick, and Matt Lucas. It revolves around an aging assassin on the verge of retirement who becomes targeted by his employer wanting to cash in on his pension. Polar was released worldwide on Netflix on January 25, 2019. A second film, The Black Kaiser, is in development.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.